Inpatient characteristics and outcomes of diffuse large B-cell lymphoma in adolescents and young adults
Recommended Citation
Olafimihan AG, Jackson I, Ntukidem OL, Ogedegbe OJ, George LJ, Ethakota J, Bai S, Farooqui MW. Inpatient characteristics and outcomes of diffuse large B-cell lymphoma in adolescents and young adults. J Clin Oncol 2025; 43(16 Suppl):e19042.
Document Type
Conference Proceeding
Publication Date
5-28-2025
Publication Title
J Clin Oncol
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is the most commonly aggressive nonHodgkin’s lymphoma known to also affect adolescents and young adults (AYA). This population faces unique challenges such as financial toxicity, physical and emotional concerns. We examined the inpatient characteristics and outcomes of AYA patients with a diagnosis of DLBCL. Methods: A retrospective cohort analysis using the Nationwide Inpatient Sample database from 2008 to 2021, DLBCL patients with non-elective hospitalizations were identified using ICD-9 and ICD-10 codes. Descriptive analyses were conducted using STATA version 17.0 to compare sociodemographic and clinical characteristics between AYA and older populations. Multivariable logistic and linear regression models were used to examine the association between the age groups and inpatient mortality, prolonged (.5 days) length of stay (LOS), and total hospital charges. Results: There were 346,185 non-elective hospitalizations with DLBCL within the 14-year study period. Of these, 23,163 (6.7%) were in the AYA cohort.The mean age was 30 years in the AYA group and 68.4 years in the older group (P=0.001). There was a higher proportion of males in the AYA group compared to the older group (59.2% vs 56.4%, P = 0.001) but a lower distribution of non-Hispanic Whites (48.6% vs 71.7%, P , 0.001). Regarding clinical characteristics, AYA-DLBCL patients had a higher frequency of febrile neutropenia (19.5 vs 13.6%, P,0.001), bone marrow transplant (4.7 vs 3.8%, P,0.004), HIV (14.5 vs 2.6%, P,0.001), superior vena cava syndrome (3.8 vs 0.9%, P,0.001) and cardiac tamponade (1 vs 0.2%, P,0.001). AYA-DLBCL patients had a lower frequency of severe sepsis (6.3 vs 8.1%, P,0.001), AKI (12.8 vs 23.6%, P,0.001), and acute respiratory failure (6.4 vs 10.5%, P,0.001). On multivariable logistic regression, the AYA group had 50% lower odds of mortality relative to the older adult group (adjusted odds ratio [aOR]: 0.51, 95% confidence interval [CI]: 0.43-0.60, P , 0.001).There was a lower odd of prolonged hospital stay in the AYA group (aOR: 0.88, 95% CI: 0.82-0.93, P , .001).TheAYA cohort had higher odds of increased hospital expenditure (b-Coefficient: 11,260, 95% CI: 3,794–18,728, P = 0.003). Conclusions: This represents the largest epidemiological study to date on DLBCL hospitalizations in AYA. The AYA cohort had lower inpatient mortality, increased hospital costs, and higher rates of febrile neutropenia and HIV. Higher hospital charges may be due to more febrile neutropenia rates, bone marrow transplants and other aggressive interventions performed in younger patients. Additional studies are needed to understand and improve long-term treatment-related toxicities in this population.
Volume
43
Issue
16 Suppl
First Page
e19042
